- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02318368
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)
A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a Phase 2 multicenter, controlled, randomized, double-blind study to evaluate the efficacy and safety of ficlatuzumab versus placebo when administered with erlotinib in subjects with previously untreated metastatic EGFR-mutated NSCLC and BDX004 Positive Label.
Prior to screening, subjects will have tested positive for a sensitizing EGFR mutation to determine eligibility for treatment with erlotinib. During screening, subject serum samples will be tested using the investigational companion diagnostic (BDX004) test. Only those subjects who have a BDX004 Positive Label will be enrolled. Subject randomization will be stratified by EGFR mutation type and smoking status (ever versus never smokers). Subjects will be designated as never smokers if they have smoked less than 100 cigarettes in their lifetime. Radiographic tumor assessment, to include CT or MRI of chest and abdomen, will be performed every 4 weeks for the first 8 cycles, and every 8 weeks thereafter, using the same imaging modality per subject. Safety assessments will be performed on an ongoing basis.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Chris O'Brien Lifehouse
-
Coffs Harbour, New South Wales, Australia, 2450
- North Coast Cancer Institute
-
Concord, New South Wales, Australia, 2139
- Concord Repatriation General Hospital
-
-
Queensland
-
Douglas, Queensland, Australia, 4814
- Townsville Hospital
-
Southport, Queensland, Australia, 4215
- Icon Cancer Care
-
Wolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5043
- Flinders Medical Centre
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Eastern Health
-
Frankston, Victoria, Australia, 3199
- Frankston Hospital
-
Wendouree, Victoria, Australia, 3355
- Ballarat Oncology and Haematology
-
-
-
-
-
Chungcheongbuk-do, Corea, república de, 362-711
- Chungbuk National University Hospital
-
Jeonnam, Corea, república de, 519-763
- Chonnam National University Hwasun Hospital
-
Seoul, Corea, república de, 135-710
- Samsung Medical Center
-
Seoul, Corea, república de, 120-752
- Severance Hospital, Yonsei Uni
-
-
Seoul
-
Guro-gu, Seoul, Corea, república de, 152703
- Korea University Guro Hospital
-
-
-
-
California
-
Fresno, California, Estados Unidos, 93701
- UCSF Fresno
-
Redondo Beach, California, Estados Unidos, 90277
- Torrance Memorial Medical Center
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33486
- Boca Raton Regional Hospital Lynn Cancer Institute
-
Deerfield Beach, Florida, Estados Unidos, 33442
- University of Miami Sylvester Comprehensive Cancer Center Deerfield Beach
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96819
- Kaiser Permanente Hawaii
-
-
Louisiana
-
Lafayette, Louisiana, Estados Unidos, 70503
- Cancer Center of Acadiana
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic
-
-
New Jersey
-
Paramus, New Jersey, Estados Unidos, 07652
- Valley Medical Group
-
-
New York
-
Jamaica, New York, Estados Unidos, 11432
- Queens Hospital Cancer Center
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44718
- Gabrail Cancer Center
-
Canton, Ohio, Estados Unidos, 44710
- Aultman Hospital
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Cancer Center Cancer
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute
-
-
-
-
-
Pok Fu Lam, Hong Kong
- Queen Mary Hospital
-
-
N.T
-
Tuen Mun, N.T, Hong Kong
- Tuen Mun Hospital
-
-
-
-
-
Benevento, Italia, 82100
- AO G.Rummo
-
Bologna, Italia, 40138
- Policlinico S.Orsola Malpighi
-
Cremona, Italia, 26100
- Istituti Ospitalieri di Cremona - Oncologia
-
Lucca, Italia, 55100
- U.O.C. Oncologia
-
Milano, Italia, 20132
- IRCCS Ospedale S.Raffaele
-
Pavia, Italia, 27100
- Fondazione Salvatore Maugeri
-
Rozzano MI, Italia, 20089
- IRCCS Istituto Clinico Humanitas
-
Treviglio BG, Italia, 24047
- Ospedale Treviglio-Caravaggio
-
-
-
-
-
Central Singapore, Singapur, 308433
- John Hopkins Singapore International Medical Center
-
Singapore, Singapur, 169610
- National Cancer Centre
-
-
-
-
-
Taichung, Taiwán, 40447
- China Medical University Hospital
-
Taichung, Taiwán, 40201
- Chung Shan Medical University
-
Tainan, Taiwán, 70403
- National Cheng Kung University
-
Taipei, Taiwán, 11696
- Taipei Medical University
-
Taipei City, Taiwán, 100
- National Taiwan University Hospital
-
Taipei City, Taiwán, 11217
- Taipei Veterans General Hospital
-
Taoyuan City, Taiwán, 333
- Chang Gung Medical Foundation
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
- Histologically and/or cytologically confirmed primary diagnosis of Stage IV NSCLC (according to American Joint Committee on Cancer [AJCC] 7th edition lung cancer staging criteria).
- Measurable disease according to RECIST v.1.1.
- An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation.
- BDX004 Positive Label.
- Have received no prior systemic chemotherapy, immunotherapy, targeted therapy, or biologic therapy for metastatic NSCLC. Subjects may have previously been treated with postoperative adjuvant chemotherapy for early stage lung cancer or chemo radiotherapy for locally advanced disease provided this was completed at least 6 months prior to enrollment. No prior EGFR TKI therapy is allowed for any stage of NSCLC.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria
- History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent or erlotinib.
- History of known brain metastases.
- Prior treatment with any other investigational drug or biologic agent within 5 half lives prior to randomization, or any investigational device within 2 weeks prior to randomization.
- Any unresolved toxicity from previous radiation therapy.
Significant cardiovascular disease, including:
- Echocardiogram (ECHO) or multiple gated acquisition (MUGA) showing left ventricular ejection fraction of less than 55%.
- Cardiac failure New York Heart Association class III or IV.
- Myocardial infarction, severe or unstable angina within 6 months prior to randomization.
- History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation).
- Significant thrombotic or embolic events within 3 months prior to randomization (significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack).
- Any uncontrolled or severe cardiovascular disease.
- History of prior malignancy within 3 years prior to randomization (except for adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or cervix, superficial bladder cancer, or early stage prostate cancer, without evidence of recurrence).
- Radiographic evidence of interstitial lung disease.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Ficlatuzumab plus erlotinib
150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
|
Otros nombres:
Otros nombres:
|
Comparador activo: Placebo plus erlotinib
150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
|
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression Free Survival (PFS)
Periodo de tiempo: Approximately 24 months
|
Progression Free Survival is defined as the time from the date of randomization to the date of the first objective documentation of radiographic disease progression or death due to any cause, whichever occurs first.
|
Approximately 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Adverse Events
Periodo de tiempo: Approximately 24 months
|
To evaluate Safety and tolerability of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic EGFR-mutated NSCLC and a BDX004 Positive Label.
|
Approximately 24 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Michael N Needle, MD, AVEO Pharmaceuticals, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Clorhidrato de erlotinib
Otros números de identificación del estudio
- AV-299-14-206
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de pulmón de células no pequeñas
-
Adelphi Values LLCBlueprint Medicines CorporationTerminadoLeucemia de mastocitos (LCM) | Mastocitosis Sistémica Agresiva (ASM) | SM w Asoc Clonal Hema Non-mast Cell Linage Disease (SM-AHNMD) | Mastocitosis sistémica latente (MSS) | Mastocitosis Sistémica Indolente (ISM) Subgrupo ISM Completamente ReclutadoEstados Unidos